Semathera Company
SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology emerges from the laboratory of Dr Mike Sapieha, Hôpital Maisonneuve-Rosement (Montreal, Canada).
Industry:
Geroscience
Headquarters:
Westmount, Quebec, Canada
Zip:
1-10
Founded Date:
2016-01-01
Employees Number:
1-10
Acquisitions Number:
2
Investors Number:
3600000
Total Funding:
3600000
Last Funding Date:
Venture - Series Unknown
Last Funding Type:
info@semathera.com
Register and Claim Ownership